In accordance with these findings, the expression of stem cell markers (NANOG and SOX2) was significantly higher in B-cell lymphoma cells survived after phenylbutyrate and doxorubicin treatment than control cells (Figure 2D). Here, SOX2 is linked to B-cell non-Hodgkin lymphoma.